This free tool tells you if Ozempic and Wegovy are in stock

Americans are using the weight-loss drugs Ozempic and Wegovy so quickly that a telehealth company developed a free tool to help patients find their next dose.

The new tracker, which telehealth company Ro announced Wednesday, allows users to report when they find a pharmacy with the drugs, known as GLP-1, in stock. A user can also report shortages to help inform others. The tool is free for everyone and is not limited to Ro customers.

Along with user information, the tool also pulls data from the Food and Drug Administration’s Drug Shortage List. Users can report shortages directly to the FDA through the tracker if they wish.

To help obtain their medications, patients can set up automatic alerts to notify them when a pharmacy in their area has some of the medications in stock. The alert also includes information to help them transfer their prescriptions. If the user is a Ro customer, the company can transfer their prescription to them.

Courtesy of Ro.

Ro CEO Zachariah Reitano said the new tracker is helping patients overcome a shortage of GLP-1, which helps treat conditions such as diabetes but has gained popularity because it can trigger weight loss.

Shortages caused by excessive demand have forced some patients in dire need of medications to travel hundreds or even thousands of miles to reach a pharmacy with medications in stock. Others have tried to use social media to help each other find medications.

“The challenges of GLP-1 shortages are exacerbated by the lack of accurate, up-to-date and accessible information on GLP-1 supply. Patients deserve better,” Reitano said in a statement.

The tracker isn’t just for patients, said Ro’s medical director, Dr. Melynda Barnes; It could also help doctors make more informed decisions.

“Providers can use the GLP-1 Supply Tracker to stay informed about supply so they can better advise their patients on the most clinically appropriate and reliable GLP-1 treatment available,” he said.
The GLP-1 shortage has led some healthcare companies, including Ro and Hims & Hers, to create lower-cost duplicates, made possible by an exception to FDA rules, to help meet demand. While Novo Nordisk’s Wegovy can cost a patient more than $1,300 without insurance, Ro’s compounded treatment uses the same active ingredient as GLP-1 and costs just $299 a month.

Sign up for Well Adjusted, our newsletter packed with simple strategies to work smarter and live better, from the Fortune Well team. Sign up for free today.

Leave a Comment